Tag: and

Communication Between Sponsors and ECs – Good Clinical Practice (GCP) and Compliance

July 8, 2025June 26, 2025

Communication Between Sponsors and ECs – Good Clinical Practice (GCP) and Compliance “Interaction Between Sponsors and Ethics Committees” Introduction Effective communication between sponsors and Ethics Committees (ECs) is crucial in the successful execution of any clinical study. It ensures ethical conduct, compliance with regulatory standards, and protection of the rights, safety, and well-being of the…

Ethics Committee Roles, Good Clinical Practice (GCP) and Compliance

Initial and Ongoing Ethical Review Responsibilities – Good Clinical Practice (GCP) and Compliance

July 7, 2025June 26, 2025

digi

Initial and Ongoing Ethical Review Responsibilities – Good Clinical Practice (GCP) and Compliance “Primary and Continuous Moral Oversight Duties” Introduction When conducting clinical studies, it is essential to maintain a strong ethical standard that ensures the safety and wellbeing of all participants involved. It’s important to not only initiate these standards at the beginning of…

Ethics Committee Roles, Good Clinical Practice (GCP) and Compliance

Structure and Composition of Ethics Committees – Good Clinical Practice (GCP) and Compliance

July 7, 2025June 26, 2025

digi

Structure and Composition of Ethics Committees – Good Clinical Practice (GCP) and Compliance “Ethics Committees: Structure and Composition” Introduction Ethics committees play a pivotal role in the realm of clinical studies, ensuring that the rights, safety, and wellbeing of human subjects are prioritized. They review, approve, and monitor biomedical research to ensure ethical guidelines are…

Ethics Committee Roles, Good Clinical Practice (GCP) and Compliance

Risk Management and Quality Assurance for Sponsors – Good Clinical Practice (GCP) and Compliance

July 7, 2025June 26, 2025

digi

Risk Management and Quality Assurance for Sponsors – Good Clinical Practice (GCP) and Compliance “Sponsor’s Risk Management and Quality Assurance Procedures” Introduction In the clinical research industry, risk management and quality assurance are two pivotal aspects that ensure the integrity of the trial, the safety of the subjects, and the validity of the data collected….

Good Clinical Practice (GCP) and Compliance, Sponsor Responsibilities

GCP Oversight of Vendors and CROs – Good Clinical Practice (GCP) and Compliance

July 6, 2025June 26, 2025

digi

GCP Oversight of Vendors and CROs – Good Clinical Practice (GCP) and Compliance “Monitoring of Vendors and CROs by GCP” Introduction to GCP Oversight Good Clinical Practice (GCP) is a set of universally accepted ethical and scientific quality standards for the design, conduct, recording, and reporting of clinical trials involving human subjects. Compliance with these…

Good Clinical Practice (GCP) and Compliance, Sponsor Responsibilities

Site Selection and Qualification Responsibilities – Good Clinical Practice (GCP) and Compliance

July 5, 2025June 26, 2025

digi

Site Selection and Qualification Responsibilities – Good Clinical Practice (GCP) and Compliance “Responsibilities for Selecting and Qualifying Sites” Introduction The selection and qualification of sites for clinical studies are crucial steps in the clinical trial process. The quality and reliability of the data collected during a clinical trial are largely dependent on the chosen sites…

Good Clinical Practice (GCP) and Compliance, Sponsor Responsibilities

Choosing Between Equivalence and Non-Inferiority – Clinical Trial Design and Protocol Development

June 24, 2025

digi

Choosing Between Equivalence and Non-Inferiority – Clinical Trial Design and Protocol Development “Deciding Between Equivalence and Non-Inferiority” Introduction Choosing the appropriate clinical trial design is a crucial step in ensuring the success of a pharmaceutical product. The decision between equivalence and non-inferiority trials often depends on the product’s intent, the competition, and the regulatory requirements….

Clinical Trial Design and Protocol Development, Non-Inferiority and Equivalence Trials

Understanding Equivalence Margins and Their Justification – Clinical Trial Design and Protocol Development

June 24, 2025

digi

Understanding Equivalence Margins and Their Justification – Clinical Trial Design and Protocol Development “Comprehending the Concept and Rationale Behind Equivalence Margins” Introduction In clinical research, statistical analysis plays a critical role in establishing the efficacy and safety of new treatments. One of the key aspects of this analysis is the determination of equivalence margins. Understanding…

Clinical Trial Design and Protocol Development, Non-Inferiority and Equivalence Trials

Blinding Integrity Checks and Audits – Clinical Trial Design and Protocol Development

June 23, 2025

digi

Blinding Integrity Checks and Audits – Clinical Trial Design and Protocol Development “Conducting Unbiased Integrity Checks and Audits” Introduction to Blinding Integrity Checks and Audits In clinical studies, maintaining blinding integrity is paramount in ensuring the validity of the study’s results. This practice minimizes bias by ensuring that the subjects, investigators, and study staff are…

Blinded Studies (Single, Double, Triple), Clinical Trial Design and Protocol Development

Unblinding Procedures and Emergency Code Breaks – Clinical Trial Design and Protocol Development

June 22, 2025

digi

Unblinding Procedures and Emergency Code Breaks – Clinical Trial Design and Protocol Development “Procedures for Unblinding and Emergency Code Breaking” Introduction to Unblinding Procedures In clinical research, blinding is a critical element in maintaining the objectivity of a study. However, sometimes, an emergency situation arises that necessitates revealing the treatment assigned to a specific patient…

Blinded Studies (Single, Double, Triple), Clinical Trial Design and Protocol Development